Navigation Links
Visceral Leishmaniasis: Successful Vaccine Trial In Dogs

Visceral leishmaniasis, which is the most severe form of that group of diseases, affects 500 000 people in the world each year. It is caused by a protozoan, Leishmania infantum, transmitted by sand fly bites. There is no vaccine for this disease, which can rapidly lead to death if no treatment is given. In the most heavily affected areas, the dog population is hit heavily by infection. It acts as parasite reservoir for humans. Development of a vaccine for dogs could help brake transmission of the disease to humans, by reducing this reservoir. Such prevention treatment has just been tested successfully on dogs by an IRD team in Montpellier, in conjunction with the Rocher veterinary clinic (La Garde, Var) and the biopharmaceutical company Bio Véto Test (La Seyne-Sur-Mer, Var). The first results showed total lasting protection of these animals against the disease, could open the way towards the development of a human vaccine.

Visceral leishmaniasis, which is the most severe form of the leishmaniases, hits an annual total of 500 000 people, mostly in the developing countries. It is caused by the parasite Leishmania infantum. A flagellate protozoan, it uses as vector an insect resembling a midge, the sand fly, colonizing the intestine and then the salivary glands. The female insect feeds on mammals?blood. It can thus pass the parasite on to humans by a single bite. Once in the blood stream, L. infantum passes into particular cells of the immune system, the macrophages. These eventually burst, releasing the parasites which move on to penetrate other cells. The infected subject suffers bouts of fever, anaemia, enlarged spleen and liver, and weight loss. In the absence of treatment, these clinical signs usually announce a fatal outcome.

The sand fly sucks blood from mammals other than humans. This is how, right around the Mediterranean rim, 5 million dogs, a proportion of from 1 to 42 % depending on the area, are affected by visceral leishmaniasis. These anim
'"/>

Source:Institut de Recherche Pour le D茅veloppement


Page: 1 2 3 4

Related biology news :

1. Successful Test Of Single Molecule Switch Opens The Door To Biomolecular Electronics
2. Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer
3. Successful cell engineering may lead to mad cow prevention, say researchers
4. Successful transplantation from pig embryos to mice
5. Successful lung cancer surgery not enough to break nicotine dependence in many smokers
6. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
7. Live Recombinant Adenovirus Vaccine Technique Explored
8. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
9. NIAID Initiates Trial of Experimental Avian Flu Vaccine
10. Study Models Impact Of Anthrax Vaccine
11. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Visceral Leishmaniasis Successful Vaccine Trial Dogs

(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
(Date:12/5/2014)... Utah , Dec. 4, 2014  Tute Genomics, ... raised $2.3 million in Series A1 funding led by ... investors also participated in the investment round. ... the healthcare community adopts next-generation sequencing and seeks new ... said Reid Robison , MD MBA, and CEO ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... 11, 2013) -- Cancer researchers from Rice University suggest that ... cancer and drug-resistant bacteria could best deliver its knockout blow ... toxins. "One of the oldest tricks in fighting ... one attack and deliver a knockout blow with another," said ...
... of UCLA-led researchers has identified a protein with broad ... weapon against deadly human pathogenic viruses such as HIV, ... pathogens" for national biosecurity purposes by the National Institute ... a study published in the January issue of the ...
... from the Empire State Building to the Golden ... remain strong and reliable. Rigiditya material,s stiffnessis of ... everything from colossal edifices to the tiniest of ... it has been difficult to measure this stiffness, ...
Cached Biology News:1-2 punch strategy against bacteria and cancer 21-2 punch strategy against bacteria and cancer 3Newly identified natural protein blocks HIV, other deadly viruses 2Visualizing biological networks in 4-D 2Visualizing biological networks in 4-D 3
(Date:12/19/2014)... In contrast to traditional LED lights where ... Valoya uses proprietary LED technology to incorporate their spectra ... which is critical in low proximity installations. The Valoya ... its lifetime which is up to four times longer ... investment cost was clearly higher when compared to traditional ...
(Date:12/19/2014)... -- Decision Resources Group finds that the Asia ... through 2023 as the aging population, increasing adoption of ... all spur procedure volumes. Growth will be particularly rapid ... and India , where rising ... a larger proportion of the population. Other ...
(Date:12/19/2014)... 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced the results of its annual general ... a transformational year in Relmada,s history and it set ... said Sergio Traversa , chief executive officer of ... key financial, human resource and clinical development objectives that ...
(Date:12/17/2014)... 2014 “Never say, ‘I cannot ... Marburg’s Department of Physics, advises young women pursuing ... released SPIE Women in Optics 18-month planner ... to ask questions.” , In the annual planner, ... occupations ranging from university professor and laboratory researcher ...
Breaking Biology Technology:Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3
... MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - YM BioSciences ... an oncology company that identifies,develops and commercializes differentiated ... from three clinical trials of its,anti-cancer drug nimotuzumab, ... factor receptor, were presented at the 2008 American,Society ...
... DIEGO, June 3 A presentation at the 14th,International ... will highlight Biocept,s I.D.Rh(D) Prenatal Diagnostic.,I.D.Rh(D) is the first ... be performed with a simple maternal blood sample., ... fetus in an Rh(D),negative pregnancy, and can be performed ...
... Microtest Laboratories,( http://www.microtestlabs.com ) has doubled ... purchase of an additional MicroSeq(R),Microbial Identification System., ... sequence-based system that,enables Microtest technicians to more ... not viable or easily identified., "With ...
Cached Biology Technology:NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 2NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 3NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 4Presentation at the 14th International Conference on Prenatal Diagnosis and Therapy Highlights Biocept's I.D.Rh(D) Prenatal Diagnostic 2Microtest Labs Doubles Microbial Identification, Analytical Services 2
...
BD Primaria 35 mm Cell Culture Dish with Easy-Grip design, surface-modified polystyrene for enhanced cell culture. (20/sp, 200/ca) Packaging: 20 / sleeve, 500 / case ...
...
BD Falcon insert HTS 96 well, square A-bottom with lid. PET membrane, sterile. (5/ca) Packaging: 5 / pack, 5 / case ...
Biology Products: